Findings

What do systematic reviews say?

27 questions · 28 findings · 4 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 17.9%GRADE not reported 6 · 21.4%Very low 4 · 14.3%Low 6 · 21.4%Moderate 0 · 0%High 7 · 25%

Riluzole vs placebo

Acquisition of the ability to sit · children with SMA type I

1 finding from 1 review

Drug treatment for spinal muscular atrophy type I 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Riluzole vs placebo

Acquisition of the ability to stand · children with SMA type I

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy type I 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Riluzole vs placebo

Change in motor score after two years · children with SMA type I

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy type I 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Riluzole vs placebo

Adverse events attributable to treatment · children with SMA type I

1 finding from 1 review

Drug treatment for spinal muscular atrophy type I 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Riluzole vs placebo

Severe adverse events attributable to treatment · children with SMA type I

1 finding from 1 review

Drug treatment for spinal muscular atrophy type I 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Riluzole vs placebo

Time from birth until death or full‐time ventilation · children with SMA type I

1 finding from 1 review

Drug treatment for spinal muscular atrophy type I 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Riluzole vs placebo

Acquisition of head control · children with SMA type I

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy type I 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Riluzole vs placebo

Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Riluzole vs placebo

Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Riluzole vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Riluzole vs placebo

Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
GRADE not reported

Riluzole vs placebo

Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Riluzole vs placebo

Economic outcomes · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intervention not reported

Mortality or tracheostomy at 12 months (pooled hazard ratio)(riluzole 100 mg) · patients with ALS/MND

The intervention showed no clear difference in mortality or tracheostomy at 12 months (pooled hazard… (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
HR 0.83 [0.7, 1]
3 studies · 1282 participants
High

Intervention not reported

Per cent mortality at 12 months (riluzole 100 mg) · patients with ALS/MND

The intervention leads to lower per cent mortality at 12 months (riluzole 100 mg) (high certainty).

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
RR 0.78 [0.65, 0.92]
3 studies · 799 participants
High

Intervention not reported

Rate of decline of Norris Scale ‐ Norris Limb (riluzole 100 mg) · patients with ALS/MND

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 731 participants
High

Intervention not reported

Rate of decline of Norris Scale ‐ Norris Bulbar (riluzole 100 mg) · patients with ALS/MND

1 finding from 1 review

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 742 participants
High

BM‐MSC vs no treatment

Functional impairment · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

2 findings from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Low
Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BM‐MSC vs no treatment

Muscle strength · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

The review found no eligible studies for this question.

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found